{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:06:17Z","timestamp":1789239977766,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Withdrawal prior to buprenorphine initiation may be intolerable or create barriers to therapy. We aim to update our previous systematic review on the efficacy and safety of buprenorphine initiation strategies that aim to omit prerequisite opioid withdrawal (POW).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used the same search strategy for this update as in the original review with the modification of an additional term \u201clow dose.\u201d We searched Embase and Scopus from April 11, 2020 to August 1, 2024 with searches in Google Scholar and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\" ext-link-type=\"uri\">www.clinicaltrials.gov<\/jats:ext-link>. A study was included if it described patients with opioid use disorder or chronic pain that transitioned from a full mu-opioid agonist to buprenorphine without preceding withdrawal and reported withdrawal during initiation as an outcome. Two investigators independently screened citations and articles for inclusion, collected data using a standardized data collection tool, and assessed study risk of bias.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty-four articles met our inclusion criteria; 31 were case reports\/series reporting 84 cases and 13 were single-arm observational studies reporting a total of 576 cases. These studies were added to the literature from our original systematic review, totaling 59 studies and 682 patients. Sublingual buprenorphine was the most common initial formulation, comprising 55% (376\/682) of cases. In case reports\/series, use of a validated scale to measure withdrawal was uncommon; validated scales were only used in 36% of patients. All other patients had withdrawal assessed in a manner not utilizing a validated scale. Approximately half of these patients experienced any level of withdrawal (57\/106\u2009=\u200954%). The specific outcome of \u201cany level of withdrawal\u201d was not consistently reported in single-arm observational studies. Eight studies reported on any level of withdrawal, which occurred in 41% (177\/428) of initiation attempts; some patients experienced more than one initiation attempt. Thirteen patients in case reports\/series and 37 patients in the single-arm observational studies reported clinically significant withdrawal (50\/682\u2009=\u20097%). 81% (451\/555) of patients transitioned to buprenorphine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The prevalence of buprenorphine dosing strategies that aim to omit POW has vastly increased over the past 4 years. While quality of evidence remains low, the increased quantity of publications and integration into health-system guidelines and protocols demonstrates the need for prospective, controlled studies. It is unknown how selection bias impacts current findings, further highlighting the need for prospective, randomized, controlled trials evaluating these dosing strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00548-z","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:53:12Z","timestamp":1740030792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review"],"prefix":"10.1186","volume":"20","author":[{"given":"Kathleen K.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Sobieraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"j1550","key":"548_CR1","first-page":"1","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357(j1550):1\u201314.","journal-title":"BMJ"},{"issue":"2S Suppl 1","key":"548_CR2","first-page":"1","volume":"14","author":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder","year":"2020","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. Practice Update. J Addict Med. 2020;14(2S Suppl 1):1\u201391.","journal-title":"J Addict Med"},{"issue":"3","key":"548_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/08897077231196417","volume":"44","author":"C Zimmerman","year":"2023","unstructured":"Zimmerman C, Clark S, Guerra ME, et al. Low dose buprenorphine initiation: a guide for the Inpatient Clinician. Substance Abuse. 2023;44(3):121\u20139.","journal-title":"Substance Abuse"},{"key":"548_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/SAR.S109919","volume":"7","author":"R H\u00e4mmig","year":"2016","unstructured":"H\u00e4mmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99\u2013105.","journal-title":"Subst Abuse Rehabil"},{"issue":"5","key":"548_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","volume":"41","author":"JP De Aquino","year":"2021","unstructured":"De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425\u201336.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"548_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/ADM.0000000000001163","volume":"17","author":"M Hardy","year":"2023","unstructured":"Hardy M, Grable S, Otley R, Pershing M. Survey of buprenorphine low-dose regimens used by healthcare institutions. J Addict Med. 2023;17(5):521\u20137.","journal-title":"J Addict Med"},{"issue":"6","key":"548_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15563650.2022.2032730","volume":"60","author":"A Spadaro","year":"2022","unstructured":"Spadaro A, Sarker A, Hogg-Bremer W, et al. Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl. Clin Toxicol (Phila). 2022;60(6):694\u2013701.","journal-title":"Clin Toxicol (Phila)"},{"issue":"6","key":"548_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","volume":"17","author":"MB Weimer","year":"2023","unstructured":"Weimer MB, Herring AA, Kawasaki SS, et al. ASAM Clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med. 2023;17(6):632\u20139.","journal-title":"J Addict Med"},{"key":"548_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13722-021-00244-8","volume":"16","author":"KK Adams","year":"2021","unstructured":"Adams KK, Machnicz M, Sobieraj DM. Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. Addict Sci Clin Pract. 2021;16:36.","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"548_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/add.15799","volume":"117","author":"MB Weimer","year":"2022","unstructured":"Weimer MB, Fiellin DA. Low- and very low\u2010dose buprenorphine induction: new(Ish) uses for an old(Ish) medication? Addiction. 2022;117(6):1507\u20139.","journal-title":"Addiction"},{"issue":"1","key":"548_CR11","doi-asserted-by":"publisher","first-page":"e00921","DOI":"10.1002\/prp2.921","volume":"10","author":"P Manandhar","year":"2022","unstructured":"Manandhar P, Connor M, Santiago M. Tapentadol shows lower intrinsic efficacy at \u00b5 receptor than morphine and oxycodone. Pharmacol Res Perspec. 2022;10(1):e00921.","journal-title":"Pharmacol Res Perspec"},{"issue":"1","key":"548_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/08897077.2021.2010250","volume":"43","author":"VR Broyan","year":"2022","unstructured":"Broyan VR, Brar JK, Allgaier T, Allgaier JT. Long-term Buprenorphine Treatment for Kratom use disorder: a Case Series. Substance Abuse. 2022;43(1):763\u20136.","journal-title":"Substance Abuse"},{"issue":"1","key":"548_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/ijamr.ijamr_58_22","volume":"9","author":"P Ganesan","year":"2022","unstructured":"Ganesan P. How to write case reports and case series. Int J Adv Med Health Res. 2022;9(1):55.","journal-title":"Int J Adv Med Health Res"},{"issue":"2","key":"548_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60\u20133. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853.","journal-title":"BMJ Evid Based Med"},{"issue":"9","key":"548_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"548_CR16","volume-title":"Revised 2019, 2020, and 2021","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2021","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for opioid use disorder. Treatment improvement protocol (TIP) series 63, full document. HHS Publication No. Publication no. PEP21-02-01-002 First released 2018. Revised 2019, 2020, and 2021. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021."},{"issue":"3","key":"548_CR17","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1503\/cmaj.74018","volume":"192","author":"PA Randhawa","year":"2020","unstructured":"Randhawa PA, Brar R, Nolan S, Buprenorphine-naloxone. Microdosing: an alternative induction approach for the treatment of opioid use disorder in the wake of North America\u2019s increasingly potent illicit drug market. CMAJ. 2020;192(3):E73.","journal-title":"CMAJ"},{"key":"548_CR18","doi-asserted-by":"publisher","first-page":"19124","DOI":"10.7812\/TPP\/19.124","volume":"24","author":"D Saal","year":"2020","unstructured":"Saal D, Lee F. Rapid induction therapy for opioid-use disorder using buprenorphine transdermal patch: a case series. Perm J. 2020;24:19124.","journal-title":"Perm J"},{"issue":"10","key":"548_CR19","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1111\/add.15942","volume":"117","author":"B Kilmer","year":"2022","unstructured":"Kilmer B, Pardo B, Pujol TA, et al. Rapid changes in illegally manufactured fentanyl products and prices in the United States. Addiction. 2022;117(10):2745\u201349.","journal-title":"Addiction"},{"issue":"4","key":"548_CR20","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","volume":"16","author":"NB Varshneya","year":"2022","unstructured":"Varshneya NB, Thakrar AP, Hobelmann JG, et al. Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med. 2022;16(4):e265\u20138.","journal-title":"J Addict Med"},{"issue":"4","key":"548_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","volume":"16","author":"KL Sue","year":"2022","unstructured":"Sue KL, Cohen S, Tilley J, et al. A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era. J Addict Med. 2022;16(4):389\u201391.","journal-title":"J Addict Med"},{"issue":"3","key":"548_CR22","doi-asserted-by":"publisher","first-page":"030201","DOI":"10.11613\/BM.2017.030201","volume":"27","author":"A Mlinari\u0107","year":"2017","unstructured":"Mlinari\u0107 A, Horvat M, \u0160upak Smol\u010di\u0107 V. Dealing with the positive publication bias: why you should really publish your negative results. Biochem Med (Zagreb). 2017;27(3):030201.","journal-title":"Biochem Med (Zagreb)"},{"issue":"8","key":"548_CR23","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the us, 2021. JAMA Netw Open. 2023;6(8):e2327488.","journal-title":"JAMA Netw Open"},{"key":"548_CR24","unstructured":"Substance Abuse and Mental Health Services Administration, Harm Reduction F. 2023. Accessed July 23, 2024. https:\/\/www.samhsa.gov\/findhelp\/harm-reduction\/framework"},{"issue":"9","key":"548_CR25","doi-asserted-by":"publisher","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","volume":"6","author":"LC Chambers","year":"2023","unstructured":"Chambers LC, Hallowell BD, Zullo AR, et al. Buprenorphine Dose and Time to Discontinuation among patients with Opioid Use Disorder in the era of Fentanyl. JAMA Netw Open. 2023;6(9):e2334540.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"548_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13722-022-00336-z","volume":"17","author":"KK Adams","year":"2022","unstructured":"Adams KK, Miech EJ, Sobieraj DM. Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis. Addict Sci Clin Pract. 2022;17(1):55.","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"548_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","volume":"30","author":"Ahmed","year":"2021","unstructured":"Ahmed, et al. Microinduction of Buprenorphine\/Naloxone: a review of the literature. Am J Addict. 2021;30(4):305\u201315.","journal-title":"Am J Addict"},{"issue":"4","key":"548_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","volume":"16","author":"SM Cohen","year":"2022","unstructured":"Cohen SM, Weimer MB, Levander XA, et al. Low dose initiation of buprenorphine: a narrative review and practical approach. J Addict Med. 2022;16(4):399\u2013406.","journal-title":"J Addict Med"},{"key":"548_CR29","doi-asserted-by":"publisher","first-page":"106740","DOI":"10.1016\/j.addbeh.2020.106740","volume":"114","author":"J Moe","year":"2021","unstructured":"Moe J, O\u2019Sullivan F, Hohl CM, et al. Short communication: systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021;114:106740.","journal-title":"Addict Behav"},{"issue":"5","key":"548_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/phar.2676","volume":"42","author":"LA Spreen","year":"2022","unstructured":"Spreen LA, Dittmar EN, QuirkKC, et al. Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review. Pharmacotherapy. 2022;42(5):411\u201327.","journal-title":"Pharmacotherapy"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00548-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:53:20Z","timestamp":1740030800000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00548-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00548-z","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}